Herein, we report. Stockhouse. (TSX: TH, Forum) noted that its Q1 2022 consolidated sales grew 20%, supported by 35% growth in sales of EGRIFTA SV formulation. See a list of the most recent Stock Forum posts on Stockhouse. Paul Levesque - President. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. - 2023 Q3 positive adjusted EBITDA to be achieved. Competitors: Unknown. S. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650 [email protected] Inc. By continuing to use our service, you agree to our use of cookies. The company was. TO) stock quote, history, news and other vital information to help you with your stock trading and investing. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced publi. By continuing to use our service, you agree to our use of cookies. This news release constitutes a “designated news release” for the purposes of the. Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors. (2022-10-26 | TSX:TH) Theratechnologies Reports Data Showing High Expression of Sortilin (SORT1) in Multiple Solid Tumors from Tissue Microarrays Stockhouse. com uses cookies on this site. By exploiting the SORT1 function in ligand internalization, a new anticancer treatment strategy was designed to target SORT1‐positive TNBC‐derived cells both in vitro and in two in vivo tumor xenografts. Theratechnologies Inc. Biopharmaceutical company Theratechnologies (TH) has closed its bought deal public offering after raising over C$58 million in proceeds. We changed the address of the Stockhouse website from to stockhouse. . Amendments Allow Theratechnologies to Maintain Minimum Liquidity of US$15 Million up to and until October 31, 2023. Cookies are used to offer you a better browsing experience and to analyze our traffic. By continuing to use our service, you agree to our use of cookies. This news release constitutes a. 1. Their average twelve-month price target is $36. (TSE:TH) posted its quarterly earnings data on Tuesday, September, 26th. Find more information. Cookies are used to offer you a better browsing experience and to analyze our traffic. GlobeNewswire. 31K. com uses cookies on this site. Theratechnologies’ Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIV. Find the latest Theratechnologies Inc. 12, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 1-438. 38. The reported ($0. Microsoft to invest $500M in Quebec AI economy. This news release constitutes a "designated news release" for the purposes of. 1 Wall Street analysts have set twelve-month price targets for Theratechnologies in the last year. THTX | Complete Theratechnologies Inc. Trogarzo® and. Register for your free account today at data. (“Theratechnologies” or the “Company”) (TSX: TH) today announced that it has applied to list its common shares on NASDAQ. By continuing to use our service, you agree to our use of cookies. Metastasis is a form of cancer that has spread from its original site to a distant site or organ where it grows or metastasizes. By continuing to use our service, you agree to our use of cookies. S. By continuing to use our service, you agree to our use of cookies. High expression of the sortilin (SORT1) receptor correlates with decreased survival in triple‐negative breast cancer (TNBC) patients. Stockhouse. S. : Nasdaq Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. Further. See the latest Theratechnologies Inc stock price (THTX:XNAS), related news, valuation, dividends and more to help you make your investing decisions. Stockhouse. Northwest also announces an update on its. Marsolais’ presentation will be available through. NCU. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Stockhouse. 11/05/2020 4:15:02 PM. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 29(+0. Theratechnologies is pepped up on peptides. By continuing to use our service, you agree to our use of cookies. 5% workforce reduction. H. com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. On July 28, 2023, Theratechnologies announced that the Company had entered into an agreement with certain funds and accounts for which Marathon Asset Management, L. Investor Relations. (TSX: EXRO) (OTCQB: EXROF) (the "Company" or "Exro" ), a leading clean technology company which has developed a new class of power electronics for electric motors and powertrains, announced today its financial results for the three months ended March 31, 2022. Volatility Over Time: TH's weekly volatility has increased from 16% to 25% over the past year. Q3 2023 consolidated revenue of $20. By continuing to use our service, you agree to our use of cookies. 14, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. T. . Top 173 largest Canadian Companies in the Drug Manufacturers—Specialty & Generic industry by Market Cap. SORT1 is a “scavenger” receptor that plays a significant role in protein internalization, sorting, and. Trogarzo ® is a long-acting, CD4-directed, post-attachment HIV-1 inhibitor. (2020-03-31 | tsx:th) theratechnologies provides business update related to current covid-19 situation Stockhouse. Cookies are used to. Marsolais will present at the H. 05M. com uses cookies on this site. 12, 2019 (GLOBE NEWSWIRE) -- Theratechnologies Inc. US Headquarters. Theratechnologies Inc (Theratechnologies) is a biopharmaceutical company that focuses on the discovery and development of drugs for people with orphan medical conditions. Small cap stock market news and analysis, portfolio tracking, investor message boards and forums (bullboards), newsletter aggregation and detailed snapshots of stock quotes for. MONTREAL, Oct. TH | May 19, 2023. : Renegotiated Lease to Generate Substantial Annual Savings Stockhouse. Q4 2022 consolidated revenue growth of 14. com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. m. European Headquarters. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a. Further. : 001-35203 Mr. 71%. Second quarter 2022 earnings: Revenues miss analyst expectations Jul 15. We also use them to share usage. Cookies are used to offer you a better browsing experience and to analyze our traffic. Stockhouse. 24, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 28, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (2013-04-03 | TSX:TH) Theratechnologies Inc. com uses cookies on this site. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced it will report financial results and provide a business update for its second. Currency in USD Follow 2W 10W 9M 1. Cookies are used to offer you a better browsing experience and to analyze our traffic. Stockhouse. TH1902 is currently Theratechnologies’ lead investigational peptide drug conjugate candidate for the treatment of cancer derived from its SORT1+ Technology™. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company will present data from tissue microarrays showing high. Real-time Price Updates for Theratechnologies (TH-T), along with buy or sell indicators, analysis, charts, historical performance, news and more(2018-03-06 | TSX:TH) Theratechnologies Announces FDA Approval of Breakthrough Therapy, Trogarzo™ (ibalizumab-uiyk) Injection, the First HIV-1 Inhibitor and Long-Acting Monoclonal Antibody for Multidrug Resistant HIV-1. Theratechnologies Unveils New Positive Data for Its Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Cancers Stockhouse. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced publi. 75. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. FAQ – Utilisateurs de TMX Argent NOUVEAU. Headquartered in Montreal, Theratechnologies is a biotech company that develops innovative therapies for unmet medical needs in HIV, oncology, and NASH, a type of liver disease. com uses cookies on this site. Theratechnologies will acquire all outstanding shares of Katana for US$5,300,000 or CA$6,900,000. T. MONTREAL, July 23, 2021 /CNW Telbec/ - Theratechnologies Inc. Investor Relations. com uses cookies on this site. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. MONTREAL, July 07, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. FY2023 Revenue Guidance Range Confirmed Between $90 million and $95 million; Growth of the Commercial Portfolio in the Range of 13% and 19%. View analysts price targets for THTX. 2022 Revenue Guidance Theratechnologies anticipates fiscal 2022 revenue to be in the range of $79 million and $84 million for full fiscal 2022, or growth of the commercial portfolio to be in the. We currently market prescription products for people with HIV in the United States. (TH) has had its first patient receive a dose of TH1902, for the treatment of sortilin positive (SORT1+) solid tumours. Cookies are used to offer you a better browsing experience and to. View real-time stock prices and stock quotes for a full financial overview. 46. T. 51 to 200 Employees. Cookies are used to offer you a better browsing experience and to analyze our traffic. Company Type For Profit. By continuing to use our service, you agree to our use of cookies. Christian Marsolais, Ph. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. 04) earnings per share (EPS) for the quarter. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Shares of Theratechnologies are up 4. It is the Company’s proprietary. communications@theratech. Rosenberg, Reference is made to your letter dated August 16, 2012 regarding the Form 40-F for fiscal year-end November 30, 2011 filed by Theratechnologies Inc. acts as investment manager. MONTREAL, April 18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies affirms fiscal 2022 revenue to be in the range of $79 million and $84 million for full fiscal 2022, or growth of the commercial portfolio to be in the range of 13% and 20% as. 521. Stockhouse. Non-Profit & Charitable Organizations · United States · <25 Employees. 39 50-Day Range $0. By continuing to use our service, you agree to our use of cookies. By continuing to use our service, you agree to our use of cookies. “This is yet another major achievement for our oncology program. Theratechnologies Inc. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis. GUD | Complete Knight Therapeutics Inc. 16, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. We currently market. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. com. Theratechnologies Inc. . - Q3 2022 Consolidated. com. TO) on CEO. 17. com uses cookies on this site. Theratechnologies Inc. Cookies are used to offer you a better browsing experience and to analyze our. By continuing to use our service, you agree to our use of cookies. 01, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Track Theratechnologies Inc. 8 million. (2022-09-19 | TSX:TH) Theratechnologies to Present at the Cantor Oncology, Hematology & HemeOnc Conference. MONTREAL, Jan. This module allows you to check different measures of market premium (i. Stockhouse. 4%. 20% from a day low at $1. (TSX-V: TLT, Forum) has demonstrated proof-of-concept for its Canadian-made COVID-19 vaccine. TH | July 20, 2023. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced dosing of the first participant in Part 3 of its Phase 1 clinical trial of. The company reported ($0. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies Inc. MONTREAL, April 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. MONTREAL, Feb. ET. 69 to $1. 54% and a negative trailing twelve-month return on equity of 1,116. TH1902 combines Theratechnologies’ proprietary peptide to. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ¨ Form 40-F xToronto, Ontario-- (Newsfile Corp. The company develops treatments for lipodystrophy . FY2023 revenue guidance range set between $90 million and $95 million. About SORT1+ Technology™ and TH1902. com 10/16/2023. Further. 2 million. 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. stock news by MarketWatch. " The 12-month stock price forecast is $18. Theratechnologies Inc. com. By continuing to use our service, you agree to our use of cookies. MONTREAL, July 14, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2023 financial results on Thursday, November 9, 2023 prior to market opening. Theratechnologies’ CFO to Attend Cantor Global Healthcare Conference in New York City. com uses cookies on this site. com. 40%) (As of 11/17/2023 ET) Compare Today's Range $1. B2Gold Declares Fourth Quarter 2023 Dividend. Join the discussion: Find out what everybody’s saying about this stock on the Theratechnologies Bullboard, and check out the rest of Stockhouse’s stock forums and message boards. communications@theratech. Cookies are used to offer you a better browsing. MONTREAL, March 07, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. MONTREAL, Feb. By continuing to use our service, you agree to our use of cookies. Approximately US$2,000,000, or CA$2,600,000, was paid in cash at closing. 26, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Type: Company - Public (TH) Revenue: $5 to $25 million (USD) Biotech & Pharmaceuticals. Stockhouse. Stockhouse. Theratechnologies Appoints New Board Member. MONTREAL, Oct. com uses cookies on this site. e. MONTREAL, June 30, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Cookies are used to offer you a better browsing experience and to analyze our traffic. 89 52. MONTREAL, June 22, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. MONTREAL, March 31, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 67% from the latest price. Montréal, Québec, Canada . MONTREAL, Nov. Montréal, Québec, Canada . On average, they expect the company's stock price to reach $36. 74M. Investor inquiries: Elif McDonald. com uses cookies on this site. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) ), a biopharmaceutical company focused on the development. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the second quarter and first half of fiscal. 617-356-1009. Thank you. TH | October 13, 2022 - Q3 2022 Consolidated. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. The Montreal-based biopharmaceutical company's consolidated net revenues for fourth quarter 2020 are expected to be between US$18. 60%. 00. Statut du système de négociation. Early Warning Report Issued Pursuant to National Instrument 62-103 - Acquisition of Securities of Theratechnologies Inc. 5000 +0. FY2023 revenue guidance range set between $90 million and $95 million. S. Stockhouse. , a biopharmaceutical company, engages in the discovery of therapeutic products for commercialization. MONTREAL, Oct. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. The Montreal-based biopharmaceutical company's consolidated net revenues for fourth quarter 2020 are expected to be between US$18. TH | February 28, 2023. 14, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company’s participation in three poster presentations at the 2022 Annual Meeting. com uses cookies on this site. 9 million as at August 31, 2023. TH | July 20, 2023. /NOT FOR DISTRIBUTION TO UNITED STATES OF AMERICA WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES OF AMERICA/. We also use them to share usage. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced it will report financial results and provide a business update for its second quarter. We also use them to share usage. By continuing to use our service, you agree to our use of cookies. (2021-11-03 | TSX:TH) Theratechnologies to Present at the Credit Suisse 30th Annual Healthcare Conference on November 11, 2021. Cookies are used to offer you a better browsing experience and to analyze our traffic. . (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced receipt of the 2023 Industrial Research Sectoral Group (RSRI) Innovation Award from the CQDM (for. 49) by $0. We currently market prescription products for people with HIV in the United States. - Q3 2022 Consolidated Revenue Growth of 17% to $20. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business. . communications@theratech. UN) today announces steps to strengthen its financial position, including financing and disposition initiatives, and a reduction to its monthly distribution. MONTREAL, Aug. Senior Director, Investor Relations. MONTREAL, Feb. In 2022, THTX's revenue was 80. By continuing to use our service, you agree to our use of cookies. Theratechnologies Reports Financial Results and Business Updates for the Fourth Quarter and Full Year Fiscal 2022. THERATECHNOLOGIES INC. 24, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. T. com. Stockhouse. . Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights. com. com uses cookies on this site. MONTREAL, Feb. Theratechnologies Provides Details About R&D Day Webcast. (2021-01-19 | TSX:TH) Theratechnologies Announces Closing of US$46 Million Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option. Contact Email communications@theratech. It engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). 22, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. It’s lead investigational peptide drug conjugate linked to docetaxel, a well-established and well-characterized cytotoxic agent used in the treatment of. The ADRIQ (Association pour le développement de la recherche et de l’innovation du Québec) rewards Quebec-based companies for leadership and innovation in their respective. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691Theratechnologies Announces Amendment to its Term Loan Facility With Affiliates of Marathon Asset Management. This work is well underway and will be considered by the SAC as part of their meeting, which is scheduled for the latter half of March when the analyses are expected to be ready. 514-336-7800. 65 per cent to C$1. Theratechnologies Inc. Wainwright NASH Investor Conference. 10% most volatile stocks in CA Market. ET. Cookies are used to offer you a better browsing experience and to analyze our traffic. One reason for that is that this tier does not include penny stocks. Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ¨ Form 40-F xMain number: 514-336-7800. - Issued and outstanding common shares to be consolidated on the basis of 1 post. Theratechnologies Unveils New Positive Data for Its Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Cancers. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (2021-06-30 | TSX:TH) CORRECTION: Theratechnologies to Announce Financial Results for Its Second Quarter Fiscal 2021. Cookies are used to offer you a better browsing experience and to analyze our traffic. , that crews have been mobilized to prepare for the 2022 exploration program at the Treaty Creek property, located in the heart of the. Cookies are used to offer you a better browsing experience and to analyze our traffic. A live webcast of Dr. Theratechnologies last announced its earnings data on September 26th, 2023. 15, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. MONTREAL, May 09, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 1-438. . . T. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. By continuing to use our service, you agree to our use of cookies. Theratechnologies Inc. Cookies are used to offer you a better browsing experience and to analyze our traffic. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650 [email protected] is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies Inc. We also use them to share usage. 6. com uses cookies on this site. Find the latest Theratechnologies Inc. We also use them to share usage information with our partners. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies,. com uses cookies on this site. 26, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Stockhouse. com uses cookies on this site. Story. MONTREAL, Oct. T. (TSX: TH, Forum) has long been a favourite among Healthcare Bullboard posters who have been following its developments to commercialize innovative therapies. We also use them to share usage information with our partners. Theratechnologies Appoints New Board Member. (TSX: TH, Forum) noted that its Q1 2022 consolidated sales grew 20%, supported by 35% growth in sales of EGRIFTA SV formulation.